 Baudax Bio NASDAQ: BXRX stock is rocketing higher on Friday after the pharmaceutical company initiated a Phase 2 clinical trial of BX1000. BX1000 is the companys drug candidate for neuromuscular blockade in patients undergoing elective surgery. 